An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19

An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19

Background: Epidemic outbreaks caused by SARS-CoV-2 are worsening around the world, and there are no target drugs to treat COVID-19. IFN-κ inhibits the replication of SARS-CoV-2; and TFF2 is a small secreted polypeptide that promotes the repair of mucosal injury and reduces the inflammatory response...

Full description

Bibliographic Details
Main Authors: Weihui Fu, Yan Liu, Li Liu, Huiliang Hu, Xiaobo Cheng, Ping Liu, Zhigang Song, Lijun Zha, Shimeng Bai, Tingting Xu, Songhua Yuan, Fengru Lu, Zhiying Shang, Yihong Zhao, Jing Wang, Jun Zhao, Longfei Ding, Jun Chen, Lin Zhang, Tongyu Zhu, Xiaoyan Zhang, Hongzhou Lu, Jianqing Xu
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:EClinicalMedicine
Subjects:
COVID-19
SARS-CoV-2
TFF2
IFN-κ
Clinical tiral
Aerosol inhalation
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537020302911

Internet

http://www.sciencedirect.com/science/article/pii/S2589537020302911

Similar Items